13th Edition Clinical Trials in Canada

$499.00

SKU: PHP11722 Category:

Description

Report Code: PHP11722. October, 2011. Toronto, ON

ARTICLE 1

Strengthening the Legislative Framework for Clinical Research in Canada

David K. Lee
Director, Health Products and Food Branch
Health Canada

ARTICLE 2

Canadian Economic Development and the Field of Clinical Research

Peter Pekos
President & CEO
Dalton Pharma Services

ARTICLE 3

Standardized Oversight of REBs in Canada: The Lost Decade

Jack Corman
President
Institutional Review Board Services

ARTICLE 4

Globalization of Clinical Research: Trends and Implications for Canada

Normand Laberge
Vice President – Regulatory & Scientific Affairs
Rx&D

ARTICLE 5

The Canadian Strategy for Patient Oriented Research (SPOR):
Clinical Trials in Canada Meeting

Jean L. Rouleau, MD
Scientific Director
CIHR Institute of Circulatory and Respiratory Health

ARTICLE 6

New Processes and Best Practices

Agnes V. Klein, MD
Biologics and Genetic Therapies Directorate
Health Canada

ARTICLE 7

Regulatory Developments at Home & Abroad: Selected Vignettes
from a Rapidly Moving Target

Jack Corman
President
Institutional Review Board Services

ARTICLE 8

Ethical Review – What Progress on the Reform Agenda?

Laurel Evans
Associate Director – Research Ethics
Office of Research Services
University of British Columbia

ARTICLE 9

Ontario’s Clinical Trials Enterprise: Building a Streamlined Ethics Review Process

Jack Holland, MD, FRCP FRCP(C)
Chair
Ontario Cancer Research Ethics Board

ARTICLE 10

Health Canada`s GCP Compliance Program

Candace Hilder
A/Manager, Good Clinical Practices Compliance Unit
Health Products and Food Branch (PFB) Inspectorate,

ARTICLE 11

Building Authentic Partnerships in Clinical Research

Sherry L. Dupuis, Ph.D.
Professor and Director
Murray Alzheimer Research and Education Program
University of Waterloo

ARTICLE 12

Using the Web to Facilitate Patient Participation in Clinical Trials

Sima Chiva-Razavi, MSc
Associate Project Manager
Abbott Laboratories Limited

ARTICLE 13

Delivering on the Promise of Pharmacogenomics

Robert Roberts, MD, FRCP(C) MACC
Director
Ruddy Canadian Cardiovascular Genetics Centre

ARTICLE 14

Canadian Clinical Research in a Global Market Place

Elaine Kielo
Clinical Operations Integration Manager
Eli Lilly

ARTICLE 15

New Models for a New Marketplace : Outsourcing, Collaborative Networks,
Reciprocal Agreements and More

Pamela Degenddorfer
Chief Operating Officer
Ozmosis Research Inc.

ARTICLE 16

New Integrated Outsourcing Model for Managing Trials

Elaine Kielo
Clinical Operations Integration Manager
Eli Lilly

ARTICLE 17

New Models for a New Marketplace: Outsourcing

Joanne E. Watson, MSc
President and CEO
Integrated Research Inc.

ARTICLE 18

Quality Assurance Strategies and Monitoring Best Practices

Pierre Gervais
President and Executive Director
Q&T Research Sherbrooke Inc.

ARTICLE 19

Quality Assurance Strategies and Monitoring Best Practices

Jason Ridderikhoff
Clinical Operations Manager
Quintiles Transnational

ARTICLE 20

Ethics, Science, and the Oversight of Clinical Research – A Brace New World Ahead?

Greg Koski, PhD, MD, CPI (Honorary)
Associate Professor of Anesthesia
Harvard Medical School

ARTICLE 21

Getting Access to Data

Khaled El Emam
Canada Research Chair in Electronic Health Information
University of Ottawa

ARTICLE 22

Regulatory Issues in Investigator Initiated Trials

Pamela Degenddorfer
Chief Operating Officer
Ozmosis Research Inc.

ARTICLE 23

Achieving Excellence in the Conduct of Investigator Initiated Research (IIR)

Lisa Johnston, RN, BScN CCRP
Research Training Coordinator, Research
Centre for Addiction and Mental Health (CAMH)

ARTICLE 24

Achieving Excellence in the Conduct of Investigator Initiated Research (IIR):
The Business Side of Investigator-Initiated Research

Margaret H. Kerr, BA, LLB, MA, PhD
Barrister & Solicitor

ARTICLE 25

SR&ED Tax Credits in the Context of Investigator-Initiated Research

Michelle Moldofsky, LLB, LLM
Policy and Legal Adviser
St. Michael’s Hospital